Chinese herbal tea to enhance stopping smoking

Effectiveness of Chinese herbal tea combined with conventional therapy for patients to stopping smoking in smoking cessation clinic: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16358150

Enrollment

Registered

2021-12-21

Start date

2022-02-01

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment for patients who are willing to stop smoking in smoking cessation clinic Not Applicable

Interventions

Experimental group: Chinese herbal tea combined with conventional therapy (based on physician prescription) for 4 weeks. Control group: conventional therapy (based on physician prescription) for 4 wee

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients in smoking cessation clinic seeking treatment. 2. Patients eligible for conventional medication. 3. The patients voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with serious diseases of the heart, lung, kidney and hematopoietic system. 2. Pregnant or lactating women. 3. Patients who are participating in other clinical trials. 4. Patients allergic to licorice and platycodon grandiflorum. 5. Patients with allergies to smoking cessation medications or similar ingredients. 6. Patients who are receiving other TCM treatments and whose TCM prescriptions include Gansui, Jingdaji, Haizao, and Yuanhua.

Design outcomes

Primary

Measure	Time frame
1. Carbon monoxide expiratory volume is measured using Carbon monoxide detector at baseline, 1day, 4 weeks. 2. Abstinence rate is measured using patients’ self-report at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks. 3. Nicotine dependence is measured using Fagerstrom test for nicotine dependence (FTND) at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks. 4. Implementation outcomes of combined Chinese herbal tea during smoking cessation treatment is measured using questionnaire and interview (containing acceptability, appropriateness, feasibility, adoption, fidelity, and sustainability) at baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks.	—

Measure

Time frame

1. Carbon monoxide expiratory volume is measured using Carbon monoxide detector at baseline, 1day, 4 weeks. 2. Abstinence rate is measured using patients’ self-report at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks. 3. Nicotine dependence is measured using Fagerstrom test for nicotine dependence (FTND) at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks. 4. Implementation outcomes of combined Chinese herbal tea during smoking cessation treatment is measured using questionnaire and interview (containing acceptability, appropriateness, feasibility, adoption, fidelity, and sustainability) at baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks.

—

Secondary

Measure	Time frame
1. Nicotine withdrawal symptoms are measured using Minnesota Nicotine Withdrawal Scale (MNWS) at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks. 2. Traditional Chinese medicine (TCM) syndrome is measured using TCM scale at baseline, 1 week, 4 weeks, 8 weeks, 12 weeks. 3. Safety outcomes are measured using blood examination (ALT, AST, GGT, BUN, Cr, UA, biochemical electrolyte) at baseline and 4 weeks. 4. Adverse events are measured using patients’ self-report at 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks during the whole course of study.	—

Measure

Time frame

1. Nicotine withdrawal symptoms are measured using Minnesota Nicotine Withdrawal Scale (MNWS) at baseline, 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks. 2. Traditional Chinese medicine (TCM) syndrome is measured using TCM scale at baseline, 1 week, 4 weeks, 8 weeks, 12 weeks. 3. Safety outcomes are measured using blood examination (ALT, AST, GGT, BUN, Cr, UA, biochemical electrolyte) at baseline and 4 weeks. 4. Adverse events are measured using patients’ self-report at 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks during the whole course of study.

—

Countries

China

Contacts

Public ContactChun-li Lu

Jennylu@bucm.edu.cn+86 15652387872

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026